4.5 Article

Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells

Related references

Note: Only part of the references are listed.
Article Chemistry, Medicinal

Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening

David Bajusz et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)

Article Chemistry, Multidisciplinary

InChI, the IUPAC International Chemical Identifier

Stephen R. Heller et al.

JOURNAL OF CHEMINFORMATICS (2015)

Review Hematology

The future of JAK inhibition in myelofibrosis and beyond

John O. Mascarenhas et al.

BLOOD REVIEWS (2014)

Review Pharmacology & Pharmacy

Selective JAK inhibitors in development for rheumatoid arthritis

Peter Norman

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)

Review Chemistry, Medicinal

Selective JAK inhibitors

Brian W. Dymock et al.

FUTURE MEDICINAL CHEMISTRY (2014)

Article Chemistry, Medicinal

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

James D. Clark et al.

JOURNAL OF MEDICINAL CHEMISTRY (2014)

Article Biochemistry & Molecular Biology

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

Luzhou Xing et al.

NATURE MEDICINE (2014)

Article Pharmacology & Pharmacy

Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

Martin E. Dowty et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)

Review Rheumatology

The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential

Maurizio Cutolo

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2013)

Article Chemistry, Medicinal

Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: Significance of the para-hydroxyl orientation

Rebekah Baskin et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)

Review Biochemistry & Molecular Biology

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

J. Mascarenhas et al.

CURRENT MEDICINAL CHEMISTRY (2012)

Review Chemistry, Medicinal

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

Peter Norman

EXPERT OPINION ON THERAPEUTIC PATENTS (2012)

Article Chemistry, Multidisciplinary

ChemProspector and generic structures: advanced mining and searching of chemical content

Valentina Eigner-Pitto et al.

Journal of Cheminformatics (2012)

Article Biochemistry & Molecular Biology

The Stilbenoid Tyrosine Kinase Inhibitor, G6, Suppresses Jak2-V617F-mediated Human Pathological Cell Growth in Vitro and in Vivo

Annet Kirabo et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

Article Biochemistry & Molecular Biology

Structure-Function Correlation of G6, a Novel Small Molecule Inhibitor of Jak2 INDISPENSABILITY OF THE STILBENOID CORE

Anurima Majumder et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2010)

Article Medicine, General & Internal

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.

Srdan Verstovsek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Chemistry, Medicinal

Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening

Robert Kiss et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)

Article Oncology

Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers

Eun Goo Jeong et al.

CLINICAL CANCER RESEARCH (2008)

Review Cell Biology

Jak2: normal function and role in hematopoietic disorders

James N. Ihle et al.

CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)

Review Oncology

Ba/F3 cells and their use in kinase drug discovery

Markus Warmuth et al.

CURRENT OPINION IN ONCOLOGY (2007)

Article Biochemistry & Molecular Biology

JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor

J Staerk et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2005)